Accretion PharmaceuticalsNSE:ACCPL +4.16%18 Gross Margin % is 28.09% as of Mar. 2026, which is 3% above its 10-year median of 27.31. GuruFocus rates NSE:ACCPL with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 935 Drug Manufacturers companies, Accretion Pharmaceuticals ranks worse than 83.74% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Accretion Pharmaceuticals had a gross margin of 28.09% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Accretion Pharmaceuticals Gross Margin % Related Terms
Accretion Pharmaceuticals Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ACCPL vs LLY, JNJ, ABBV: Gross Margin % Comparison
For the Drug Manufacturers - General subindustry, Accretion Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accretion Pharmaceuticals Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accretion Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Accretion Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Accretion Pharmaceuticals (NSE:ACCPL) has a Gross Margin % of 28.09% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Accretion Pharmaceuticals and its competitors. This is near median its historical median of 27.31. Over the past decade, Accretion Pharmaceuticals' Gross Margin % has ranged from 20.54 to 35.81. According to the industry distribution chart, Accretion Pharmaceuticals ranks #783 out of 935 companies in the Drug Manufacturers industry, placing it in the top 83.7%.
Is Accretion Pharmaceuticals' Gross Margin % too high?
Accretion Pharmaceuticals' current Gross Margin % of 28.09% is near median its 10-year median of 27.31. Over the past 10 years, this metric has ranged from a low of 20.54 to a high of 35.81. The Drug Manufacturers industry median Gross Margin % is 48.54. Accretion Pharmaceuticals' value of 28.09% is 42.1% below this industry median. Based on the distribution chart, Accretion Pharmaceuticals ranks #783 out of 935 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Accretion Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Pharmaceuticals' Gross Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Accretion Pharmaceuticals ranks #783 out of 935 companies for Gross Margin %. This places Accretion Pharmaceuticals in the lower half of its industry. The industry median Gross Margin % is 48.54. Accretion Pharmaceuticals' value of 28.09% is 42.1% below this benchmark. Historically, Accretion Pharmaceuticals' own Gross Margin % has ranged from 20.54 to 35.81 over the past decade. While the company's 10-year median is 27.31 vs. the industry median of 48.54, Accretion Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accretion Pharmaceuticals's current Gross Margin % of 28.09% is 42.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Accretion Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Pharmaceuticals's current Gross Margin % is 28.09%, which is near median its own 10-year median of 27.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Pharmaceuticals stock overvalued right now?
Accretion Pharmaceuticals (NSE:ACCPL) has a current Gross Margin % of 28.09%. The current Gross Margin % is 28.09%, which is near median its 10-year median of 27.31 and 42.1% below the Drug Manufacturers industry median of 48.54. Accretion Pharmaceuticals' overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Accretion Pharmaceuticals (NSE:ACCPL), the current Gross Margin % is 28.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accretion Pharmaceuticals Ltd is engaged in the manufacturing of Medicinal & Pharmaceutical Products. The company manufactures tablets, oral liquid, capsule, cream, ointment, mouthwash, dusting powder, gel, ear drops, lotion, shampoo, powder, syrup, among others.
18GF Score
Get the complete analysis for NSE:ACCPL
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ACCPL has been successfully added to your 